🇺🇸 FDA
Patent

US 10653749

Targeting GIV-GEF-GI signaling for treating diverse diseases

granted A61KA61K38/00A61K38/1741

Quick answer

US patent 10653749 (Targeting GIV-GEF-GI signaling for treating diverse diseases) held by The Regents of the University of California expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K38/00, A61K38/1741, A61K38/179, A61P